500
The journal Clinical Therapeutics has published an article with the topic “What Can Big Data Offer the Pharmacovigilance of Orphan Drugs”. The pharmacovigilance of drugs for orphan diseases presents problems related to the small patient population. Obtaining high-quality information on individual reports of suspected adverse reactions is of particular importance for the pharmacovigilance of orphan drugs. The possibility of mining “big data” to detect suspected adverse reactions is being explored in pharmacovigilance generally but may have limited application to orphan drugs. The full-text article you can find here.